Squarepoint’s Aratana Therapeutics, Inc. PETX Stock Holding History

Squarepoint’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-34,200	Closed	-$123K	–	2817
2019 Q1	$123K	Buy	+34,200	New	+$148K	﹤0.01%	2014
2018 Q4	–	Sell	-28,213	Closed	-$165K	–	2410
2018 Q3	$165K	Sell	28,213 -10,236	-27%	-$51.1K	﹤0.01%	1811
2018 Q2	$163K	Buy	38,449 +27,263	+244%	+$137K	﹤0.01%	1574
2018 Q1	$49K	Buy	+11,186	New	+$49.9K	﹤0.01%	1612
2017 Q1	–	Sell	-29,773	Closed	-$214K	–	2106
2016 Q4	$214K	Buy	+29,773	New	+$241K	0.01%	1395
2016 Q1	–	Sell	-46,000	Closed	-$257K	–	1582
2015 Q4	$257K	Buy	+46,000	New	+$304K	0.03%	871

Other funds holding PETX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OAC

OMERS Administration Corp Toronto, Ontario, Canada $15.6B AUM 24.73% 1-Year Est. Return

Squarepoint's PETX Position: Q2 2019 in Review

Squarepoint sold out of Aratana Therapeutics, Inc. (PETX) in Q2 2019, closing a stake of 34,200 shares — an estimated $123K sold.

Squarepoint first reported a position in PETX in Q4 2015 and held it in 6 quarters. The position peaked at $257K in Q4 2015. 103 funds tracked by Wall St. Rank hold PETX as of Q2 2019.

Squarepoint reported no remaining Aratana Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
Squarepoint sold 34,200 Aratana Therapeutics, Inc. shares in Q2 2019, an estimated $123K.
Squarepoint first reported a position in Aratana Therapeutics, Inc. in Q4 2015 and held it in 6 quarters.
Squarepoint's Aratana Therapeutics, Inc. position peaked at $257K in Q4 2015.
103 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q2 2019.

Based on Squarepoint's 13F filing for Q2 2019, filed 14 Aug 2019.